Amgen added to uncertainty…
Amgen added to uncertainty surrounding the OX40 drug class by [...]
The majority of Bristol Myers…
The majority of Bristol Myers Squibb’s $48.2 billion revenue haul [...]
Astellas surpassed market…
Astellas surpassed market expectations in its third-quarter fiscal year 2025 [...]
F.T.C. Settles With Express Scripts Over High Insulin Prices
The Trump administration announced that the company, a pharmacy benefit [...]
Novo Nordisk Warns of First Sales Drop Since Start of Ozempic
The once high-flying Danish drugmaker has struggled to fend off [...]
Bristol Myers Squibb has signed…
Bristol Myers Squibb has signed Kasey Keller for a Breyanzi [...]
Charles River Laboratories is…
Charles River Laboratories is continuing its run of layoffs by [...]
As top-selling Keytruda inches…
As top-selling Keytruda inches closer to its 2028 patent cliff, [...]
La ostarina, el fármaco que está en el centro del dopaje deportivo
El fármaco prometía profundos cambios en tratamientos médicos. Algo inesperado [...]
AstraZeneca will have to negotiate…
AstraZeneca will have to negotiate what appears to be a [...]